Zika Virus Treatment

NIAID is supporting the development of treatments for Zika virus infection, including using its suite of preclinical services to examine drug compounds and molecules for activity against Zika virus, as well as to test treatments in animal models of Zika virus infection. NIAID is also working to screen a library of approved drugs for potential activity against Zika. One goal is to develop a broad-spectrum antiviral drug that could be used to treat a variety of flaviviruses, including Zika.

Further, NIAID is supporting efforts to develop monoclonal antibodies capable of neutralizing Zika virus.

Content last reviewed on September 8, 2017